Pipeline
Curatis identifies potential drug candidates for a repurposing development approach in indications with high unmet medical needs via its extensive network within the scientific and medical community, as well as within the biotech/pharmaceutical industry. Curatis invests a significant portion of its revenues and resources in its development activities.
The current pipeline is a balance of preclinical and clinical compounds with clinically validated targets.
| Molecule | Pre-clinical | Phase I | Phase II | Phase III | Market |
|---|---|---|---|---|---|
| C-H-01 | prevention of frequent episodic tension type headache | ||||
| C-M-01 | prevention of severe migraine with aura | ||||
| C-ALS-01 | ALS* | ||||
*Amyotrophic lateral sclerosis